top of page

Xontogeny's Chris Garabedian gives a year-end review and looks ahead to biotech's 2024

Chris Garabedian's thoughts on the IPO market, products vs platforms, and why it is a good thing that the correction has injected more discipline and prioritization to biotech.


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page